

# Sharon A Chung

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9760866/publications.pdf>

Version: 2024-02-01

43  
papers

3,923  
citations

293460

24  
h-index

312153

41  
g-index

44  
all docs

44  
docs citations

44  
times ranked

5245  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply. Arthritis and Rheumatology, 2022, 74, 545-546.	2.9	0
2	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care and Research, 2022, 74, 538-548.	1.5	13
3	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis and Rheumatology, 2022, 74, 586-596.	2.9	13
4	Endovascular Therapy for Intracranial Giant Cell Arteritis. Clinical Neuroradiology, 2022, , 1.	1.0	4
5	Dynamics of Methylation of CpG Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort. Arthritis and Rheumatology, 2022, 74, 1676-1686.	2.9	5
6	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. Arthritis and Rheumatology, 2021, 73, 512-519.	2.9	34
7	Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 101-110.	0.9	12
8	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	2.6	26
9	Takayasu Arteritis: a Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 80-90.	0.9	9
10	Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 91-100.	0.9	6
11	Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 196-205.	0.9	10
12	Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 429-441.	0.9	20
13	Neurological manifestations of polyarteritis nodosa: a tour of the neuroaxis by case series. BMC Neurology, 2021, 21, 205.	0.8	3
14	Kawasaki Disease: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 671-683.	0.9	2
15	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care and Research, 2021, 73, 1088-1105.	1.5	90
16	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis and Rheumatology, 2021, 73, 1366-1383.	2.9	249
17	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis and Rheumatology, 2021, 73, 1349-1365.	2.9	231
18	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis and Rheumatology, 2021, 73, 1384-1393.	2.9	32

#	ARTICLE	IF	CITATIONS
19	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. <i>Arthritis Care and Research</i> , 2021, 73, 1061-1070.	1.5	15
20	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 1071-1087.	1.5	61
21	A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. <i>Nature Communications</i> , 2019, 10, 3902.	5.8	39
22	149â€¦Network-based analysis of clinical and molecular data in a multiethnic lupus cohort identifies molecular associations with serological manifestations. , 2019, , .		0
23	The Right Frame. <i>Journal of Hospital Medicine</i> , 2019, 14, 246.	0.7	0
24	DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity. <i>Lupus Science and Medicine</i> , 2018, 5, e000285.	1.1	52
25	Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematosus patients. <i>PLoS ONE</i> , 2018, 13, e0199003.	1.1	46
26	Analysis of pulmonary features and treatment approaches in the COPA syndrome. <i>ERJ Open Research</i> , 2018, 4, 00017-2018.	1.1	71
27	Primary Angiitis of the Central Nervous System. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 503-518.	0.8	24
28	Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type 1 interferon responses. <i>Lupus Science and Medicine</i> , 2016, 3, e000183.	1.1	54
29	Current Treatment of Cryoglobulinemic Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 213-224.	0.6	5
30	Rare variants, autoimmune disease, and arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 346-351.	2.0	13
31	Genome-Wide Assessment of Differential DNA Methylation Associated with Autoantibody Production in Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0129813.	1.1	51
32	Lupus Nephritis Susceptibility Loci in Women with Systemic Lupus Erythematosus. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2859-2870.	3.0	117
33	Differential Genetic Associations for Systemic Lupus Erythematosus Based on Anti-â€œdsDNA Autoantibody Production. <i>PLoS Genetics</i> , 2011, 7, e1001323.	1.5	206
34	Risk Alleles for Systemic Lupus Erythematosus in a Large Case-Control Collection and Associations with Clinical Subphenotypes. <i>PLoS Genetics</i> , 2011, 7, e1001311.	1.5	154
35	A Comprehensive Analysis of Shared Loci between Systemic Lupus Erythematosus (SLE) and Sixteen Autoimmune Diseases Reveals Limited Genetic Overlap. <i>PLoS Genetics</i> , 2011, 7, e1002406.	1.5	148
36	Microscopic Polyangiitis. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 545-558.	0.8	106

#	ARTICLE	IF	CITATIONS
37	High-Density SNP Screening of the Major Histocompatibility Complex in Systemic Lupus Erythematosus Demonstrates Strong Evidence for Independent Susceptibility Regions. <i>PLoS Genetics</i> , 2009, 5, e1000696.	1.5	109
38	European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 60, 2448-2456.	6.7	27
39	A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. <i>Nature Genetics</i> , 2009, 41, 1228-1233.	9.4	729
40	Advances in the use of biologic agents for the treatment of systemic vasculitis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 3-9.	2.0	31
41	Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus. <i>PLoS Genetics</i> , 2008, 4, e1000084.	1.5	180
42	Association of Systemic Lupus Erythematosus with <i>C8orf13</i> and <i>ITGAM</i> . <i>New England Journal of Medicine</i> , 2008, 358, 900-909.	13.9	848
43	<i>PTPN22</i> : Its role in SLE and autoimmunity. <i>Autoimmunity</i> , 2007, 40, 582-590.	1.2	77